Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Diluted Average) (2020 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $98.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 8.95% to $98.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $98.6 million, a 8.95% increase, with the full-year FY2025 number at $98.6 million, up 8.95% from a year prior.
  • Shares Outstanding (Diluted Average) was $98.6 million for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $98.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $98.6 million in Q4 2025 to a low of $67.8 million in Q4 2021.
  • A 5-year average of $80.5 million and a median of $72.2 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 1.23% in 2023, then skyrocketed 34.52% in 2024.
  • Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) stood at $67.8 million in 2021, then rose by 3.13% to $69.9 million in 2022, then increased by 5.13% to $73.5 million in 2023, then increased by 23.13% to $90.5 million in 2024, then increased by 8.95% to $98.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Shares Outstanding (Diluted Average) are $98.6 million (Q4 2025), $98.2 million (Q3 2025), and $98.5 million (Q2 2025).